Literature DB >> 17214851

Analysis of the CC chemokine receptor 5 delta32 polymorphism in a Brazilian population with cutaneous leishmaniasis.

Karen Brajão de Oliveira1, Edna Maria Vissoci Reiche, Helena Kaminami Morimoto, Maria Helena Pelegrinelli Fungaro, Dirceu Estevão, Rubens Pontello, Thiago Franco Nasser, Maria Angelica Ehara Watanabe.   

Abstract

Patients with mucocutaneous leishmaniasis (MCL) show a vigorous T-cell immune response against Leishmania braziliensis. Because the Th response is associated with inflammation, the non-functional CC chemokine receptor 5 (CCR5) may rely in a less severe inflammatory state. The aim of this study was to investigate the CCR5 gene in a Brazilian population with leishmaniasis compared with healthy control subjects and to determine the progression from cutaneous to MCL in the Delta32 allele carriers. Among 100 patients with Montenegro skin test and indirect immunofluorescence assay (IIF) values positive for leishmaniasis, there were 32% women and 68% men. The patients were 89% CCR5/CCR5, 10% CCR5/Delta32, and 1% Delta32/Delta32, while healthy subjects showed a 91% incidence of CCR5/CCR5, 8% of CCR5/Delta32, and 1% of Delta32/Delta32. The CCR5/CCR5 patients (89%) showed a large spectrum of clinical manifestations, where 22.47% had active mucous lesions and 77.53% had cutaneous lesions. In this work, the Delta32 allele carriers (10%) showed only cutaneous manifestations when compared with wild-type individuals. Finally, with regard to the Delta32 allele carriers, a less severe spectrum of clinical manifestations was observed in comparison with wild-type individuals. Although a lack of mucocutaneous lesions was evident among Delta32 allele carriers, the number of individuals studied was small. Therefore, further investigations are needed to elucidate the role of CCR5 in the clinical aspects of leishmaniasis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17214851     DOI: 10.1111/j.1600-0560.2006.00573.x

Source DB:  PubMed          Journal:  J Cutan Pathol        ISSN: 0303-6987            Impact factor:   1.587


  6 in total

1.  Regulatory T-Cell Dynamics in Cutaneous and Mucocutaneous Leishmaniasis due to Leishmania braziliensis.

Authors:  Nicolas Barros; Nestor Vasquez; Fernando Woll; Cesar Sanchez; Braulio Valencia; Alejandro Llanos-Cuentas; A Clinton White; Martin Montes
Journal:  Am J Trop Med Hyg       Date:  2018-02-01       Impact factor: 2.345

2.  Association study of CCR5 delta 32 polymorphism among the HLA-DRB1 Caucasian population in Northern Paraná, Brazil.

Authors:  Sandra Marcia Muxel; Sueli Donizete Borelli; Marla Karine Amarante; Julio Cesar Voltarelli; Mateus Nobrega Aoki; Carlos Eduardo Coral de Oliveira; Maria Angelica Ehara Watanabe
Journal:  J Clin Lab Anal       Date:  2008       Impact factor: 2.352

3.  Analysis of the CCR5 gene coding region diversity in five South American populations reveals two new non-synonymous alleles in Amerindians and high CCR5*D32 frequency in Euro-Brazilians.

Authors:  Angelica B W Boldt; Lodércio Culpi; Luiza T Tsuneto; Ilíada R Souza; Jürgen F J Kun; Maria Luiza Petzl-Erler
Journal:  Genet Mol Biol       Date:  2009-01-16       Impact factor: 1.771

4.  Disease severity in patients infected with Leishmania mexicana relates to IL-1β.

Authors:  Edith A Fernández-Figueroa; Claudia Rangel-Escareño; Valeria Espinosa-Mateos; Karol Carrillo-Sánchez; Norma Salaiza-Suazo; Georgina Carrada-Figueroa; Santiago March-Mifsut; Ingeborg Becker
Journal:  PLoS Negl Trop Dis       Date:  2012-05-22

5.  Absence of Association between CCR5 rs333 Polymorphism and Childhood Acute Lymphoblastic Leukemia.

Authors:  Carlos Eduardo Coral de Oliveira; Marla Karine Amarante; Aparecida de Lourdes Perim; Patricia Midori Murobushi Ozawa; Carlos Hiroki; Glauco Akelinghton Freire Vitiello; Roberta Losi Guembarovski; Maria Angelica Ehara Watanabe
Journal:  Adv Hematol       Date:  2014-04-13

Review 6.  CCR5Δ32 in Brazil: Impacts of a European Genetic Variant on a Highly Admixed Population.

Authors:  Bruna Kulmann-Leal; Joel Henrique Ellwanger; José Artur Bogo Chies
Journal:  Front Immunol       Date:  2021-12-10       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.